TAS-102 plus Bevacizumab combination as salvage therapy in elderly patients with metastatic colorectal cancer, phase 2 trial - TAS-102 plus Bevacizumab as salvage therapy in elderly patients with metastatic colorectal cancer

Tokushima University Hospital0 个研究点目标入组 25 人开始时间: 2016年4月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) patient who had previously received chemotherapy with TAS-102 2) patient who has history of hemoptysis(>=25mL, fresh blood) 3) patient with other active malignancies 4) patient with symptomatic brain metastasis 5) patients with serious pleural effusion, ascites or pericardial effusion 6) patients with active infection 7) Patient with interstitial pneumonia or lung fibrosis confirmed in imaging study 8) patient who has important clinical complications(symptomatic unstable ischemic heart disease, arrhythmia, acute myocardial infarction within 6 months, liver cirrhosis, renal failure, active gastrointestinal ulcer, ileus, uncontrolled diabetes, uncontrolled hypertension, etc.) 9) patient with non-healing wound or traumatic bone fracture 10) patient with bleeding disorders or current use of anticoagulant 11) patient with severe drug allergy 12) male patient who hoping partner's pregnancy 13) patient who has at least either one of HIV antibody, HBs antigen, or HCV antibody 14) patient who given a dicision of unsuitable for this study by the investigator

发起方